Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
As a result, Heartseed has successfully produced high-purity cardiomyocytes consistently from all iPS cell lines used in this study.
- As a result, Heartseed has successfully produced high-purity cardiomyocytes consistently from all iPS cell lines used in this study.
- This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine, which uses iPS cells obtained from the patient's own cells.
- However, the differentiation efficiency of iPS cells into target cells varies, and in order to efficiently produce cardiomyocytes from different donor-derived iPS cells, it is necessary to optimize the method of cardiomyocyte production for each iPS cell.
- Heartseed and I Peace will continue to work towards establishing regenerative medicine using patients' own iPS cells.